Merck Close to $6 Billion Deal to Acquire Terns Pharma, FT Says

Global pharmaceutical giant Merck is reportedly nearing a major acquisition worth nearly $6 billion, according to a Financial Times report. The deal involves U.S.-based biotech company Terns Pharmaceuticals and reflects a broader shift in the healthcare industry as large drugmakers race to strengthen their future drug pipelines.

The potential acquisition has already sparked strong reactions in the stock market, with investors closely watching how the move could reshape oncology innovation and long-term revenue growth.

Details of the Reported Acquisition

According to multiple reports citing sources familiar with the matter, Merck is close to finalizing an all-cash deal valued at approximately $6 billion to acquire Terns Pharma. Negotiations are said to be in advanced stages, and an announcement could come within days if talks conclude successfully.

The proposed deal would value Terns at a premium compared to its market capitalization of about $5.3 billion, signaling strong confidence in the company’s drug development pipeline.

Following the news, Terns Pharma shares surged nearly 10 percent in after-hours trading, showing immediate investor enthusiasm.

Why Merck Is Pursuing This Acquisition

The primary driver behind the acquisition is Merck’s need to prepare for the upcoming patent expiration of its blockbuster cancer drug Keytruda, which generates roughly $30 billion annually in revenue. Keytruda’s patent protection could begin expiring as early as 2028, creating significant pressure on future earnings.

To offset this risk, Merck has been aggressively investing in biotechnology companies to secure next-generation treatments. Key strategic goals include:

• Expanding oncology research capabilities.
• Replacing future revenue losses.
• Strengthening early-stage drug pipelines.
• Maintaining leadership in cancer therapies.

Industry analysts view this acquisition as a defensive yet strategic move to ensure long-term growth.

What Terns Pharma Brings to the Table

Terns Pharmaceuticals focuses on developing therapies for chronic myeloid leukemia (CML), a rare cancer affecting blood and bone marrow. Its lead experimental treatment targets genetic mutations responsible for cancer cell growth. If successful, the therapy could compete with existing treatments from major pharmaceutical rivals.

For Merck, acquiring Terns would add promising oncology assets at a critical time when innovation is essential to sustain revenue momentum. The acquisition also aligns with Merck’s ongoing restructuring efforts, including building a dedicated cancer-focused business division.

Merck’s Broader Dealmaking Strategy

The reported deal is not an isolated move. Over the past year, Merck has accelerated acquisitions and partnerships across biotechnology. Recent transactions include:

• A $10 billion acquisition of Verona Pharma.
• A $9.2 billion purchase of Cidara Therapeutics.
• Multiple research collaborations targeting oncology innovation.

These deals highlight how large pharmaceutical companies are reshaping portfolios ahead of an industry-wide patent cliff expected to impact hundreds of billions in revenue by 2030. Analysts say the current environment rewards companies that secure future drug pipelines early rather than relying on aging blockbuster medicines.

Impact on the Stock Market and Investor Sentiment

The acquisition news has influenced investor discussions across biotech and healthcare equities. Pharmaceutical mergers often trigger market reactions because they signal:

• Confidence in future drug development.
• Expansion into high-growth therapeutic areas.
• Long-term revenue stability.

Institutional investors conducting detailed stock research are increasingly focusing on pipeline strength rather than current sales alone. Merck’s shares have shown resilience in recent years, partly due to investor approval of its acquisition-driven strategy.

Healthcare companies are also gaining attention alongside technology-focused AI stocks, as artificial intelligence becomes essential in drug discovery and clinical trials.

Role of AI in Modern Drug Development

Artificial intelligence is transforming pharmaceutical research by accelerating drug discovery timelines. AI tools help companies:

• Analyze biological data faster.
• Predict treatment effectiveness.
• Reduce clinical trial costs.
• Identify promising molecules earlier.

Merck has expanded digital and AI-supported research initiatives, which could enhance the value of Terns’ experimental therapies after acquisition. This intersection of biotech and AI innovation is becoming an important theme within the modern stock market.

Potential Risks and Challenges

Despite positive investor reaction, several risks remain.

Clinical Trial Uncertainty

Early-stage drugs carry significant failure risks. A clinical setback could reduce the expected value of the acquisition.

High Acquisition Costs

At $6 billion, the deal represents a major capital commitment. Analysts note that successful commercialization will be essential to justify the investment.

Competitive Oncology Landscape

Rival pharmaceutical companies are also investing heavily in cancer treatments, increasing competition for market share.

Experts warn that execution will be critical once integration begins.

Industry Trend Toward Biotech Acquisitions

The pharmaceutical sector is currently experiencing a wave of mergers and acquisitions.Large drugmakers are seeking innovative biotech firms because:

• Drug patents are expiring globally.
• Research costs continue rising.
• Smaller biotech firms drive innovation.
• Investors reward pipeline expansion.

The global industry could face more than $320 billion in revenue losses from patent expirations by the end of the decade, pushing companies toward aggressive dealmaking strategies.

Merck’s potential purchase of Terns fits squarely within this trend.

What Analysts Expect Next

Market analysts believe the deal could close soon if negotiations proceed smoothly. Key developments investors will monitor include:

• Official acquisition announcement.
• Regulatory approvals.
• Clinical trial updates.
• Integration plans for Terns’ research programs.

If completed, the acquisition may strengthen Merck’s long-term oncology position and support earnings stability beyond 2028. For investors following healthcare equities, this deal highlights how pharmaceutical innovation and strategic acquisitions remain powerful drivers of valuation.

Conclusion

The reported $6 billion acquisition of Terns Pharma marks a pivotal moment for Merck as it prepares for a future beyond its blockbuster cancer drug revenues. By investing heavily in promising oncology treatments, the company aims to secure long-term growth and maintain leadership in one of the most competitive healthcare sectors.

The move also reflects broader changes shaping the global stock market, where innovation, AI-supported research, and pipeline strength increasingly determine investor confidence. As pharmaceutical companies adapt to patent expirations and scientific breakthroughs, strategic acquisitions like this may become the defining trend of the decade.

FAQs

Disclaimer:

The content shared by Meyka AI PTY LTD is solely for research and informational purposes. Meyka is not a financial advisory service, and the information provided should not be considered investment or trading advice.